SGLT2 inhibition slows tumor growth in mice by reversing hyperinsulinemia
ConclusionsTaken together, these data demonstrate that hyperinsulinemia per se promotes both breast and colon cancer progression in obese mice, and highlight SGLT2 inhibitors as a clinically available means of slowing obesity-associated tumor growth due to their glucose- and insulin-lowering effects.
Source: Cancer and Metabolism - Category: Cancer & Oncology Source Type: research
More News: Adenocarcinoma | Breast Cancer | Cancer | Cancer & Oncology | Colon Cancer | Colorectal Cancer | Dapagliflozin | Eating Disorders & Weight Management | Forxiga | Hormones | Insulin | Obesity | SGLT2 Inhibitors | Sodium | Weight Loss